CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2011, and company highlights.
“2011 was a year of remarkable clinical achievement for Alnylam and for RNAi therapeutics. Notably, we reported on positive clinical data in three distinct programs over the past 12 months, including human proof of RNAi mechanism in our ALN-VSP liver cancer program, human proof of concept in our ALN-TTR program for transthyretin-mediated amyloidosis, and clinical efficacy in our ALN-PCS severe hypercholesterolemia program,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “With these important accomplishments in hand, we are now more confident than ever in our ability to harness the RNAi pathway for the development of high impact, innovative medicines as defined in our ‘Alnylam 5x15’ product strategy, focused on genetically defined targets and diseases with high unmet medical need.”
